Ads
related to: how much progesterone per day calculator cme for texas nurses statelearn.uptodate.com has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
150 mg/day or 200 mg twice daily Finasteride: Propecia: 5αR inhibitor: Oral: 1–5 mg/day Dutasteride: Avodart: 5αR inhibitor: Oral: 0.25–0.5 mg/day Progesterone: Prometrium [c] Progestogen: Oral: 100–400 mg/day Medroxyprogesterone acetate: Provera: Progestogen: Oral: 2.5–40 mg/day Depo-Provera: Progestogen: IM: 150 mg every 3 mos: Depo ...
Progesterone is used as part of hormone replacement therapy in people who have low progesterone levels, and for other reasons. For purposes of comparison with normal physiological circumstances, luteal phase levels of progesterone are 4 to 30 ng/mL, while follicular phase levels of progesterone are 0.02 to 0.9 ng/mL, menopausal levels are 0.03 to 0.3 ng/mL, and levels of progesterone in men ...
100 μg/day Insignificant 146 L/day 700–3600 pmol/L 250–1300 pg/mL Luteal phase 180 μg/day Insignificant 146 L/day 1100–7300 pmol/L 400–2600 pg/mL Progesterone: Follicular phase 2 mg/day 1.7 mg/day 2100 L/day 0.3–3 nmol/L 0.1–0.9 ng/mL Luteal phase 25 mg/day 24 mg/day 2100 L/day 19–45 nmol/L 6–14 ng/mL
There is a case report of progesterone misuse with an oral dosage of 6,400 mg per day. [137] Administration of as much as 500 mg progesterone by intravenous infusion in humans was uneventful in terms of toxicity, but did induce deep sleep, though the individuals were still able to be awakened with sufficient stimulation. [119] [17] [120] [121]
MPA has been studied at "massive" dosages of up to 5,000 mg per day orally and 2,000 mg per day via intramuscular injection, without major tolerability or safety issues described. [ 122 ] [ 123 ] [ 124 ] Overdose is not described in the Food and Drug Administration (FDA) product labels for injected MPA (Depo-Provera or Depo-SubQ Provera 104).
A 2012 meta-analysis estimated that the absolute risk of VTE is 2 per 10,000 women for non-use, 8 per 10,000 women for ethinylestradiol and levonorgestrel-containing birth control pills, and 10 to 15 per 10,000 women for birth control pills containing ethinylestradiol and a newer-generation progestin. [76]